Malena Cohen-Cymberknoh M.D.

Pediatric Pulmonologist, Hadassah University Hospital

Airway epithelial cells and immune cells contribute to the inflammatory process found in the CF lung. Intense bronchial neutrophilic inflammation and release of proteases and oxygen radicals perpetuate the vicious cycle and damage the airways. Measuring airway inflammation is essential for initiating treatment and monitoring its effect. No inflammatory biomarker directly predicting the clinical course of CF lung disease is currently known, although neutrophil elastase seems to correlate with lung function decline. The role of anti-inflammatory agents in CF has been the subject of intense investigation, and some anti-inflammatory therapies have been shown to significantly reduce the rate of respiratory exacerbations and cause slight improvement in pulmonary function.